Please assess the completion status of the following clinical trial:

Trial Title: Scandinavian Bell's Palsy Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~1. Be in good general health and between 18 and 75 years of age.~2. Have an acute peripheral unilateral idiopathic facial palsy.~3. Not more than 72 hours must have passed after onset of palsy before initiating study medication.~4. The subjects must provide their freely given written informed consent.~Exclusion Criteria:~1. Subjects who have used any antiherpetic medication, except locally applied formulations, within the last 2 weeks.~2. Subjects with ongoing systemic steroid medication for another disease.~3. Pregnant women or nursing mothers.~4. Subjects with diabetes.~5. Subjects presently suffering from gastric or duodenal ulcers. If there is a history of previous peptic ulcers or dyspepsia prophylactic medication must be prescribed and taken during study.~6. Subjects with a history of tuberculosis.~7. Subjects with psychiatric diagnosis that are at risk to be influenced by the study drugs or that might affect the patient´s ability to complete this study.~8. Subjects with a hypertension not well controlled.~9. Subjects with a present, or a history of, serious heart disease.~10. Subjects with a history of glaucoma.~11. Subjects with a history of hepatic disease.~12. Subjects with other neurological diseases.~13. Subjects with a history of renal diseases or a known creatinine clearance of \< 30mL/min.~14. Subjects with acute otitis or a history of ipsilateral chronic otitis.~15. Subjects with a history of recent head injury.~16. Fertile, sexually active women not employing acceptable methods of contraception and/or women planning to become pregnant during the period with intake of study medication.~17. Subjects with a history of immunodeficiency syndromes.~18. Subjects with an allergy or sensitivity to aciclovir or valaciclovir, famciclovir or ganciclovir.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None
- 2 (Type: EXPERIMENTAL): None
- 3 (Type: EXPERIMENTAL): None
- 4 (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).